FULC fades after a big move for a SHORT tradeFULC a biotechnology firm with a mixed earnings report early in the month just
printed a big move and then stalled at the NY lunch - hour and faded. Will the fade
continue or will there be an upward continuation? The 15 -minute chart seems to suggest
a downtrend:
1, The volume profile shows heavy trading at the top. This could be short sellers and
late-coming long trades. Once a trend down is underway, the short sellers will begin to
take profits buying to cover while the long trades will sell at a loss. Probably at this level
there will be more longs exiting than shorts until a substantial fall dictates the latter
to buy to cover.
2. New short sellers will pile into the trade pushing price down while few new long traders
will participate in accelerating the move down.
3. The relative strength on that indicator falling confirms the trend as does the Average Positive
Directional Index falling with the combined falling as well.
4. The mass index indicator documents a reversal
Accordingly,
I will take a short trade and assist the trend down in my own little way. I may take a trade of
100 shares and then sell a call option. In the meanwhile, I will take a put option striking
$5.00 for September 15th. I expect a decent realized profit from these trades in this
at least currently high volatility biotechnology penny stock.
FULC
FULC Biotech Fib Level BouncdFULC on the 15 minute chart had a good response to favorable earnings and then retraced.
It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume
profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling
volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10% price
rise in the after-hours which is typically a busy trading period for biotechnology penny stocks.
I will take a long trade on FULC in after hours and take off a part of the position in the next
trading day and hold the rest through the weekend.
FULC SendFULC news catalyst popped the stock into the previous gap and right back to testing this clear resistance level that was previous support. After plotting the fib retracement is looks like the 50 Fib line is an area that might need to set up as the higher support level if there's any hope of FULC sustaining higher levels. We'll have to see what happens next.
"The company focuses on developing treatments for rare genetic diseases. including sickle cell disease. This week, the company announced key data that has helped drive momentum in the market and push shares of FULC stock higher. Fulcrum announced positive interim results from its ongoing single- and multiple ascending dose (SAD and MAD) Phase 1 trial with FTX-6058. This treatment targets patients with fetal hemoglobin (HbF) with the potential to treat hemoglobinopathies."
Quote Source & Read More: Hot Stocks To Watch On Robinhood With Analyst Targets Up To 368%